Semax at a Glance

• Semax is the synthetic heptapeptide Met-Glu-His-Phe-Pro-Gly-Pro built from the ACTH(4–7) fragment Met-Glu-His-Phe with a C-terminal Pro-Gly-Pro extension added to slow enzymatic degradation. It is conventionally described as an analogue of ACTH(4–10).
• It was developed in the Soviet Union and Russia from the 1980s, principally at the Institute of Molecular Genetics in Moscow, and is registered as a medicine in Russia for neurological indications. It has no approval in the United States, the European Union or the United Kingdom.
• The mechanistic literature centres on BDNF and NGF expression trkB signalling and a melanocortin-related relationship to the parent ACTH sequence. Semax was designed to lack the corticotropic activity of ACTH.
• The peptide was designed for intranasal delivery and rat pharmacokinetic work supports rapid appearance in brain tissue after nasal administration.
• Almost the entire evidence base is one national literature. The ischaemic stroke and cognition work is predominantly Russian, frequently published in Russian-language journals, and no large Western randomised controlled trial exists. An independent assessment by the Alzheimer’s Drug Discovery Foundation’s Cognitive Vitality programme concluded that published literature of well-conducted studies is lacking.
• Semax is not FDA-approved and is not a dietary supplement ingredient. Material sold for laboratory work is research-use-only.

What Is Semax?

Semax is a seven-residue synthetic peptide sequence Met-Glu-His-Phe-Pro-Gly-Pro (MEHFPGP) with a molecular weight of approximately 813.9 Da. The parent structure is catalogued in PubChem as ACTH(4-7), Pro-Gly-Pro-, CID 9811102, with the molecular formula C₃₇H₅₁N₉O₁₀S and it carries CAS number 80714-61-0.

Its design is worth understanding in detail, because it explains most of what the pharmacology literature claims.

The first four residues are a natural ACTH fragment. Met-Glu-His-Phe corresponds to residues 4–7 of adrenocorticotropic hormone. The wider ACTH(4–10) region had been studied since the 1960s for behavioural and memory effects that appeared to be independent of adrenal steroid release a body of work associated with David de Wied and the concept of neuropeptides with direct central actions. That fragment is, however, degraded within minutes.

The Pro-Gly-Pro tail is a stability device, not a pharmacophore. Appending the tripeptide Pro-Gly-Pro to the C-terminus substantially slows proteolysis: proline-rich sequences are poor substrates for many peptidases, and the terminal proline blocks carboxypeptidase attack. The Russian literature treats Pro-Gly-Pro as a “glyproline” motif with its own modest activity, and one line of work has examined the C-terminal PGP fragment separately from the parent peptide.

Corticotropic activity was deliberately excluded. The adrenal-stimulating region of ACTH lies outside residues 4–10, so Semax retains the putative neurotropic portion of the hormone without the endocrine effect. This is the design claim that makes the compound interesting as a research tool rather than as a corticosteroid-releasing agent.

A related compound, N-acetyl semax amidate (NASA) is sold in the same catalogues and is a different molecule: N-terminal acetylation and C-terminal amidation further block terminal degradation. Findings from Semax studies should not be assumed to transfer to it.

How Does Semax Work?

Neurotrophin Expression: BDNF and NGF

The best-supported mechanism, and the one most often cited, is upregulation of neurotrophins.

Dolotov and colleagues (2006, PMID 16996037) reported in Brain Research that Semax, described as an analogue of ACTH(4–10) with cognitive effects, regulates BDNF and trkB expression in the rat hippocampus. Companion work from the same group in Journal of Neurochemistry reported that the peptide binds specifically in rat brain tissue and increases BDNF protein levels in the basal forebrain which is the closest thing in the literature to evidence of a discrete binding site.

Related work has reported increases in nerve growth factor expression and in NGF-dependent signalling in rat brain, and effects on trophic-factor genes and their receptors under ischaemic conditions (PMID 19024553).

This is a conventional neuropharmacological account with a nameable target family, and it is the main respect in which Semax differs from the Khavinson-programme bioregulators it is often sold alongside. Two caveats: the binding work has not been extended into a receptor identification, and neurotrophin induction is a downstream readout that many interventions produce.

Melanocortin-Related Signalling

Because Semax derives from ACTH, the melanocortin receptor family (MC1R–MC5R) is the obvious candidate target, and MC4R in particular is expressed widely in brain and implicated in behaviour and neuroprotection.

The honest position is that Semax has not been shown to act as a conventional melanocortin receptor agonist. The ACTH(4–10) behavioural literature was built specifically on effects that appeared to dissociate from classical melanocortin endocrine signalling, and the contemporary Semax literature generally describes melanocortin involvement as a structural relationship and a plausible pathway rather than a demonstrated mechanism. Readers should treat “melanocortin mechanism” in secondary coverage of this compound as a hypothesis inherited from the parent sequence.

Transcriptional Responses in Cerebral Ischaemia

The most distinctive body of mechanistic work is transcriptomic, and it points somewhere unexpected.

Medvedeva and colleagues (2014, PMID 24661604) performed genome-wide transcriptional analysis in rats after permanent middle cerebral artery occlusion, with Semax administered intraperitoneally at 100 µg/kg at several time points after occlusion. They reported that the peptide predominantly enhanced the expression of genes related to the immune system at 24 hours, immune-response genes accounted for more than half of the transcripts showing Semax-induced change, alongside changes in vascular genes involved in endothelial development and smooth muscle cell migration.

Proteomic work has followed the same direction: a 2021 study in International Journal of Molecular Sciences reported that the brain protein expression profile in a rat cerebral ischaemia–reperfusion model was consistent with a protective effect (PMC8226508).

The interpretive point is that the neurotrophin story and the transcriptomic story are not the same story. The BDNF account is a plasticity mechanism; the transcriptomic account is closer to immunomodulation and vascular support during acute injury. Both may be true, but no unifying model predicts which applies in which paradigm, and this is one reason the compound is hard to position.

The Intranasal Route

Semax was formulated for nasal administration in Russian clinical practice, and the design rationale is straightforward: a 814 Da hydrophilic peptide has negligible oral bioavailability and poor passive blood–brain barrier permeability, and nasal delivery offers both rapid systemic absorption and a possible direct olfactory pathway to brain.

Rodent pharmacokinetic work supports rapid appearance in brain after nasal dosing (PMID 16523722), and related work on the peptide’s PGP-containing metabolites has examined brain penetration by intranasal versus intravenous routes.

Two qualifications matter. Rodent nasal anatomy differs substantially from human, with a proportionally far larger olfactory epithelium, so nose-to-brain transfer efficiency does not scale directly. And demonstrating that a peptide reaches brain tissue is not the same as demonstrating that the quantity reaching it is pharmacologically meaningful.

Research Evidence

Animal Models of Ischaemia and Cognition

This is the deepest part of the dataset. Rodent work has examined Semax in global cerebral ischaemia (PMID 11188738) and in experimental ischaemic infarction of the cerebral cortex where neuroprotective and antiamnesic effects were reported (PMID 17603664). Further work examined optic nerve models and haemorheological endpoints including erythrocyte deformability in ischaemic rats.

Doses in this literature are reported in micrograms per kilogram by intraperitoneal or intranasal administration, 100 µg/kg is a commonly used figure in the transcriptomic work. These are reported here strictly as the cited rodent studies describe them for those specific models; they are not recommendations and do not translate to other species or routes.

The limitation is provenance rather than design. Individual studies are often methodologically reasonable, but the overwhelming majority originate from a small set of collaborating Moscow institutes, and independent replication outside that network is scarce.

The Russian Clinical Stroke Literature

Semax entered Russian clinical practice for acute ischaemic stroke and related neurological indications, and there is a clinical literature to match. Representative work includes a clinical and electrophysiological study of effectiveness in the acute period of hemispheric ischaemic stroke (PMID 11517472), alongside published series examining patients at different stages of ischaemic stroke and reports of increased BDNF in treated patients.

Western reviewers treat this literature cautiously, and the reasons are specific rather than dismissive:

• Publication language and venue. Much of it appears in Russian-language journals with limited international indexing, so abstracts are often all that is accessible in English. That impedes assessment of randomisation, blinding, allocation concealment and analysis population.
• Trial design and scale. The studies are generally small by contemporary stroke-trial standards, where neuroprotection trials have repeatedly required thousands of participants to detect modest effects.
• The base rate for neuroprotection is poor. Dozens of neuroprotective agents have shown benefit in rodent stroke models and failed in adequately powered human trials. A positive small human trial in this field carries less prior weight than it would elsewhere.
• No registered, blinded multi-centre Western replication exists. A search of ClinicalTrials.gov does not return a completed large randomised trial of Semax with published results.

None of that establishes that the Russian findings are wrong. It establishes that they are unconfirmed by the mechanism science normally uses to confirm things and that is the correct summary.

Cognitive and Attention Research

The nootropic claim rests on a thinner base than the stroke claim. Kaplan and colleagues reported in 1996 that the synthetic ACTH analogue Semax displayed nootropic-like activity in humans, and small studies have reported effects on attention, memory performance and electrophysiological measures in healthy participants.

The independent assessment is the most useful anchor here. The Alzheimer’s Drug Discovery Foundation’s Cognitive Vitality review of Semax noted two pilot studies in healthy individuals reporting fMRI changes and memory improvements, and two stroke studies reporting neurological improvement and increased BDNF, while concluding that there is little evidence whether it would improve cognition in healthy people and no evidence in Alzheimer’s disease and that published literature of well-conducted studies is lacking. It also recorded reported adverse events from Russian use including nasal discoloration and elevated blood glucose in people with diabetes, and noted that long-term effects are unknown.

What Remains Unknown

No receptor has been identified. Specific binding has been reported in rat brain tissue, but no receptor, transporter or binding protein has been cloned or characterised, and the melanocortin hypothesis remains a structural inference.

Human pharmacokinetics are essentially uncharacterised. Rodent nasal kinetics exist; there is no substantial published human PK dataset establishing plasma or CSF exposure, and for a peptide expected to be cleared within minutes this is a significant gap.

The mechanistic accounts are not reconciled. Neurotrophin induction, immune-gene modulation and monoamine effects have each been reported, with no model specifying which dominates in which paradigm.

The cognitive claim in healthy subjects is largely untested. Most human work is in patients with cerebrovascular disease. Extrapolating from injury models to enhancement in intact brains is a substantial and unvalidated leap.

Comparison: Semax, Selank, Epithalon and Pinealon

These four are routinely grouped as “Russian research peptides” and sold together, but they differ sharply in mechanism and in evidence quality, which is the axis worth comparing.

Selank is the closest structural relative: the same Pro-Gly-Pro stabilising strategy applied to a fragment of the immunomodulatory peptide tuftsin, studied principally as an anxiolytic. A review of the molecular aspects of its biological activity (PMID 30255741) sets out the GABAergic and enkephalin-related account. Its evidence base has the same national concentration as Semax’s.

Epithalon and Pinealon sit in a different evidential category despite being sold in the same listings. Both come from the Khavinson peptide-bioregulator programme, and their proposed mechanism, that short peptides enter the nucleus and act directly on gene expression, is a far stronger claim than anything asserted for Semax. An independent 2025 review of Epitalon noted that despite the volume of biological research, physico-chemical and structural investigation of the peptide remains quite limited (PMID 40141333). Catalogues list Epithalon and Pinealon as separate research compounds.

The practical conclusion for a laboratory: Semax has the most conventional pharmacological account of the four a nameable target family, reported specific binding, and a measurable downstream readout in BDNF. That is a difference of mechanistic specificity, not of evidential independence. All four remain dominated by one national literature.

Handling and Reconstitution of Lyophilised Semax

At seven residues and roughly 814 Da, Semax is a short linear peptide and handles simply, with two chemistry-specific points worth knowing.

The methionine residue is the oxidation liability. Met is the most readily oxidised of the common amino acids, and methionine sulphoxide formation is the realistic degradation product for this peptide. Oxidation is promoted by dissolved oxygen, trace transition metals, light and elevated temperature. In practice this means minimising headspace air in stock solutions, avoiding unnecessary metal contact, protecting solutions from light, and keeping them cold. A supplier’s chromatogram should ideally resolve the sulphoxide, which typically elutes earlier than the parent peptide on reverse phase.

The histidine and glutamate residues make pH relevant. Histidine’s imidazole ionises near physiological pH and glutamate is acidic, so the molecule’s net charge and solubility shift across a narrow pH range. Aqueous solubility is nonetheless good and no organic co-solvent is normally required.

The Pro-Gly-Pro tail that makes the peptide relatively protease-resistant in vivo does not make it resistant to microbial contamination in a vial. A short peptide in an unpreserved aqueous solution at room temperature is a growth substrate, and contamination is a far more common cause of a failed experiment than chemical degradation.

Practical reconstitution follows the standard sequence: equilibrate the vial to room temperature before opening so moisture does not condense on the cold cake, disinfect the septum with 70% isopropyl alcohol and let it dry, introduce the diluent slowly down the inner wall of the vial rather than onto the cake, and swirl or roll gently rather than shaking.

Where a vial will be entered repeatedly, a preserved monographed bacteriostatic water, listed beside the research compounds themselves at NextGenPeps, is the conventional laboratory choice, and Bacteriostatic Water for Injection, USP is what most protocols specify. Two caveats belong in the record. The benzyl alcohol preservative is not inert toward peptides, the formulation literature documents preservative-promoted unfolding and aggregation across model peptides, so single-entry analytical preparations are better served by unpreserved sterile water. And it is contraindicated in neonatal use because of benzyl alcohol toxicity, a restriction that belongs in handling notes even where no clinical use is contemplated.

Store reconstituted solution at 2–8 °C, aliquot at the point of reconstitution rather than freeze–thawing repeatedly, record concentration in mg/mL rather than “volume added,” and log the diluent lot alongside the peptide lot.

Is Semax FDA Approved?

No. Semax is not approved by the FDA, the EMA or the MHRA for any indication, in any species. There is no US marketing authorisation, no approved labelling and no approved route of administration.

Its regulatory history elsewhere is genuinely unusual and should be reported accurately. Semax is registered as a medicine in Russia where it has been used in neurological practice, principally for cerebrovascular indications, and is available as a nasal formulation. That registration was granted under Russia’s own regulatory framework and reflects the domestic evidence base described above. It is not transferable. Approval in one jurisdiction says nothing about status under FDA or EMA review, neither of which has evaluated the compound, and the existence of a registered product is not evidence that a Western regulator would reach the same conclusion on the same dossier.

Semax is likewise not a lawful dietary supplement ingredient in the United States. A synthetic heptapeptide does not qualify as a dietary ingredient, and marketing it for human consumption places it outside both the drug and the supplement frameworks.

One further part of the record is often misdescribed. The FDA maintains a list of certain bulk drug substances for use in compounding that may present significant safety risks. Semax appears in the record of that process as a withdrawn nomination rather than as a substance on the active list. Neither inclusion on nor absence from that list constitutes approval, and the list governs pharmacy compounding, not research use.

The practical consequence is the ordinary one: material purchased for laboratory work is research-use-only no Western regulator has assessed the identity, purity or safety of any research-grade lot, and supplier documentation carries the entire evidentiary burden.

Where to Source Research-Grade Semax

A seven-residue peptide is straightforward to synthesise, which means the market contains both competent material and material made cheaply and badly. A defensible purchase record contains:

• A lot-matched certificate of analysis tied to the specific lot shipped rather than to a representative batch.
• Third-party HPLC purity data with a named laboratory, a stated method and a test date. For this sequence the impurities that matter are methionine sulphoxide deletion sequences from incomplete coupling, and des-proline species from the Pro-Gly-Pro tail. All require a reasonably resolved chromatogram to see; a flat trace with a stated percentage is not data.
• Mass spectrometry confirming identity with an observed mass consistent with the expected ~814 Da. Note that methionine sulphoxide is only +16 Da, so the MS record should be read alongside the chromatogram rather than instead of it.
• Confirmation that the material is Semax and not N-acetyl semax amidate. These are different molecules with different masses and different published literatures, and the distinction is sometimes blurred in listings.
• Declared net peptide content distinct from gross vial fill weight, and residual trifluoroacetate data where available, since TFA from reverse-phase purification contributes mass and is cytotoxic at low concentrations in cell work.
• Cold, dry, light-protected storage and shipping and explicit research-use-only labelling with no suggested protocol, dosing guidance or human-use framing anywhere in the listing.

Red flags in this market are more often editorial than analytical. A listing that presents the Russian stroke results as established efficacy, describes Semax as a proven nootropic, or treats Russian registration as equivalent to FDA approval has overstated a literature that independent Western reviewers describe as insufficiently well-conducted to judge. Listings quoting nasal drop counts or human regimens are a compliance signal about the supplier, independent of product quality.

A catalogue that lists Semax as a research compound can be assessed against exactly these criteria: lot-matched third-party analysis with a resolved chromatogram, confirmed identity by mass spectrometry, unambiguous distinction from the acetylated-amidated analogue, declared net peptide content, residual solvent figures, and research-use-only labelling with no protocol content attached. The same checklist applies to any supplier.

Frequently Asked Questions

Is Semax an ACTH(4-10) analogue or an ACTH(4-7) analogue?

Both descriptions appear, and both are defensible. The first four residues of Semax correspond to ACTH(4–7), and the added Pro-Gly-Pro occupies the position of residues 8–10 in a modified form. The literature most often calls it an ACTH(4–10) analogue because it was designed against that fragment’s behavioural pharmacology, while chemical descriptions favour ACTH(4–7)PGP.

Does Semax increase BDNF?

In rat brain, published work reports that it does. A 2006 Brain Research study reported regulation of BDNF and trkB expression in rat hippocampus, and companion work reported increased BDNF protein in basal forebrain alongside specific binding in brain tissue. Whether this translates to meaningful BDNF changes in humans, at what exposure, is not established by an adequate human dataset.

Why do Western reviewers treat the stroke data cautiously?

Because the studies are small by stroke-trial standards, largely published in Russian-language journals with limited indexing, and unreplicated outside the research network that produced them. Neuroprotection is also a field with an unusually poor record of translation: many agents effective in rodent stroke models have failed in adequately powered human trials, so a positive small trial carries less prior weight than it would elsewhere.

Is Semax approved in Russia?

Yes. Semax is registered as a medicine in Russia and has been used in neurological practice there, in a nasal formulation. That registration was granted under Russia’s own framework and confers no status under FDA or EMA review. Neither agency has evaluated the compound.

Why is Semax given intranasally rather than orally?

Because an 814 Da hydrophilic peptide has negligible oral bioavailability, it would be digested, and poor passive blood–brain barrier permeability. Nasal delivery gives rapid systemic absorption and a possible direct olfactory route to brain. Rodent work supports rapid brain appearance after nasal dosing, though rodent nasal anatomy differs substantially from human and the efficiency does not scale directly.

How does Semax differ from N-acetyl semax amidate?

They are different molecules. NASA adds N-terminal acetylation and C-terminal amidation, further blocking terminal proteolysis and changing the mass. The published Semax literature was generated with Semax, and findings should not be assumed to transfer. Any certificate of analysis should make clear which compound was supplied.

What is the single biggest gap in the Semax evidence base?

Independent replication. The mechanistic work is more conventional and better specified than for most research peptides in this category, but almost the entire dataset, preclinical and clinical, originates from one national research network. No large, registered, blinded Western randomised trial has tested any Semax claim.

The Bottom Line

Semax occupies an unusual position: it has a more conventional pharmacological account than most peptides sold alongside it and a less independent evidence base than its clinical registration implies.

What is reasonably supported: the molecule is a well-defined heptapeptide with a rational design, a natural ACTH fragment with a proteolysis-blocking tail and the corticotropic region deliberately excluded. Reported specific binding in rat brain tissue and BDNF and trkB regulation in hippocampus give it something closer to a real target hypothesis than the bioregulator peptides it shares catalogue space with. The rodent ischaemia literature is reasonably deep, and the transcriptomic and proteomic work adds a coherent secondary account centred on immune and vascular gene expression during acute injury.

What is not supported: the nootropic claim in healthy people which rests on a handful of small studies and which an independent Western assessment concluded there is little evidence for. The stroke efficacy claim which has a real clinical literature that has never been tested in a large blinded registered trial and which sits in a field with a poor translational record. A defined receptor which does not exist. And human pharmacokinetics which are essentially uncharacterised.

The most important thing to hold onto is structural rather than scientific: almost all of this is one national literature. That is not evidence of error, and the Russian neuropeptide programme produced genuinely interesting molecules. But independent replication is how science removes group-specific artefacts, and for Semax that process has largely not happened. The compound is a legitimate object of neurotrophin and ischaemia research. It is not an established nootropic, and the literature does not support describing it as one.

By [AUTHOR NAME PLACEHOLDER], [CREDENTIALS PLACEHOLDER]. Fact-checked by [FACT-CHECKER NAME PLACEHOLDER].

Research Use Only Disclaimer

Semax, Selank, Epithalon, Pinealon and all other compounds discussed in this article are intended for laboratory research use only. Semax is not approved by the U.S. Food and Drug Administration, the European Medicines Agency or any comparable authority for the diagnosis, treatment, cure or prevention of any disease, in any species, and is not an approved dietary supplement ingredient in the United States. Registration of Semax as a medicine in the Russian Federation is reported here as a matter of regulatory record and confers no status under FDA or EMA review, no endorsement of efficacy and no permission for use elsewhere.

Nothing in this article is medical, veterinary or pharmaceutical advice, and nothing in it constitutes a dosing recommendation, a protocol for use in humans or animals, or a therapeutic claim of any kind. Peptides described here are not for human or veterinary use. Doses and concentrations quoted from the literature are reported in the terms the original investigators used for the specific model studied and are not recommendations, conversions or equivalents for any other species or route. Descriptions of published findings, including reported effects on BDNF, cognition or stroke outcomes, are summaries of what the cited literature reports, not endorsements of those findings. Readers with clinical questions should consult a qualified healthcare professional. Bacteriostatic Water for Injection, USP contains benzyl alcohol and is contraindicated in neonates. Readers are responsible for compliance with all applicable laws, institutional review and animal ethics requirements, anti-doping regulations and biosafety rules in their jurisdiction.

Related posts:

Visualization in the Pediatric Patient Nerve Monitoring Factors in a Standard Work Protocol for Adult Deformity Surgery Medical Complications Peptides for Anxiety: Research, Potential Mechanisms, and What to Know

Stay updated, free articles. Join our Telegram channel

Join